People in the News

Apr 18, 2018

Linda McAllister

Linda McAllister has been named CMO of Revelar Health, which is developing a breath-based test to measure aldehyde concentrations. McAllister was previously the VP of scientific affiars and innovations at Becton Dickinson. Before that, she was a consultant to early-stage device and diagnostic companies. She also has been CMO at Xagenic, CellScape, PharmaJet, and Arbor Vita. 

Apr 16, 2018

John Lubniewski

John Lubniewski has been promoted by HTG Molecular Diagnostics to president and chief operating officer. Lubniewski has been the company's chief business officer for the past seven years. He joined HTG from Ventana, now part of Roche, where he held several senior leadership roles, and was responsible for marketing and global accountability for all assay products. Prior to joining Ventana, he was with Corning.

Apr 16, 2018

Michael Ropacki

Amarantus Bioscience appointed Michael Ropacki as chief medical advisor to its alzheimer's blood diagnostic LymPro test program. Ropacki will be responsible for helping oversee the further development of LymPro. He will also assist a management team currently being recruited to lead the firm's neurodiagnostics division in raising capital for a neurodiagnostics subsidiary that it will soon establish. Amarantus noted that Ropacki brings more than 20 years of clinical development experience as a clinical leader, investigator, and consultant.

Apr 16, 2018

Richard Williams

Richard Williams has become managing director and head of oncology programs at WuXi Nextcode. He joins the company from Grail, where he was lead medical director of the Circulating Cell-Free Genome Atlas program. Prior to that, he held positions in oncology drug development at Amgen and at Puma Technology. Williams holds B.Med.Sc and PhD degrees, as well as bachelor of medicine and bachelor of surgery degrees, from the University of Queensland in Australia.

Apr 13, 2018

Irwin Jacobs, Martin Wygod

Biological Dynamics has added Irwin Jacobs and Martin Wygod to its board of directors. Jacobs is a cofounder of semiconductor and telecommunications equipment firm Qualcomm, as well as chairman emeritus of the Salk Institute for Biological Studies. Wygod is director of Medco Containment Services and former chairman of WebMD Health. 

Apr 13, 2018

Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, Robin Patel

Curetis has established a US scientific advisory board consisting of five infectious disease experts. Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, and Robin Patel will support the clinical adoption of the firm's Unyvero System and lower respiratory tract infection assay recently cleared by the US Food and Drug Administration. 

Goff is currently an infectious diseases specialist with the One Health Antibiotic Stewardship team at The Ohio State University; Mildvan is professor of medicine at Icahn School of Medicine at Mount Sinai in New York; Miller is director of the clinical molecular microbiology laboratory at the University of North Carolina at Chapel Hill School of Medicine; Nolte is medical director of clinical labs and molecular pathology at the Medical University of South Carolina; and Patel is co-director of the clinical bacteriology laboratory, director of the infectious diseases research lab, and chair of the division of clinical microbiology at Mayo Clinic.

Apr 13, 2018

Heidi Rehm

Heidi Rehm last month became chief genomics officer in the Department of Medicine at Massachusetts General Hospital, where she is part of the Center for Genomic Medicine. In her new role, she will focus on the clinical implementation of genomics. Rehm remains medical director of the Broad Institute’s clinical research sequencing platform and an associate professor of pathology at MGH, Brigham and Women’s Hospital, and Harvard Medical School. She is also a leader and principal investigator of ClinGen, and a co-leader of the Broad Center for Mendelian Genomics. Previously, Rehm was the director of the Laboratory for Molecular Medicine at Partners Healthcare Personalized Medicine.

Apr 13, 2018

Michael Murray

Michael Murray has become director for clinical operations in the Center for Genomic Health at Yale University School of Medicine. He joins Yale from the Geisinger Health System, where he was director of clinical genomics and was leading the GenomeFIRST return of results program, which is part of Geisinger’s MyCode Community Heath Initiative. In his new role at Yale, he will similarly focus on bringing clinical genomics to large patient cohorts.

Apr 11, 2018

Kenneth Berlin

Rosetta Genomics President and CEO Kenneth Berlin is resigning from the company effective April 18 to pursue other opportunities. He will assist the company in a smooth transition with ongoing projects, the company said. Berlin joined Rosetta Genomics in November 2009 as president and CEO. Before that, he was worldwide general manager at Veridex, a Johnson & Johnson company. He joined J&J in 1994 and was its corporate counsel for six years, according to Rosetta Genomics' website. From 2001 to 2004, he was vice president of licensing and new business development in the pharmaceutical group at J&J, and from 2004 to 2007, he was worldwide VP of franchise development at Ortho Clinical Diagnostics, also a J&J company. 

Apr 10, 2018

James Mock

PerkinElmer has appointed James Mock as senior vice president and CFO, effective May 1. Mock will replace Andy Wilson as CFO. Wilson, who previously announced his retirement from PerkinElmer, will remain with the company as an advisor for an interim period to ensure a smooth integration, the firm said. Mock has served for nearly 20 years in a wide range of financial oversight capacities within General Electric, most recently as vice president of GE's corporate audit staff, where he worked on controllership reviews and operational excellence projects. 

Apr 10, 2018

David Rappaport

OraSure Technologies has appointed David Rappaport senior vice president of business development. He had been senior vice president, healthcare investment banking at Raymond James. Prior to that, Rappaport was a healthcare investment banker with Inverness Advisors, Theomas Weisel Partners, and SG Cowen. 

Apr 10, 2018

Matthew Strobeck

Quidel has appointed Matthew Strobeck, managing partner of Birchview Capital, to the company's board of directors after increasing the size of its board from seven to eight members. Strobeck was previously with Westfield Capital Management and currently serves on the boards of Accelerate Diagnostics and Biodesix.

Apr 10, 2018

Dirk Ehlers

Centogene has appointed Dirk Ehlers its chief operating officer and president of the diagnostics division. He joins the company from Hill-Rom Holdings where he was senior vice president and president of the sugical solutions division and served on the Group Executive Team. Before that, he was CEO of Eppendorf, and he has held management positions at Roche, Fresenius Kabi, Olympus Optical, and Evotec.

Apr 09, 2018

Tom Lindsay

Genedrive has appointed Tom Lindsay as a non-executive director, effective immediately. Lindsay most recently was at Alere, where he held roles including president of Africa, president of commercial operations in Africa, and business development director for Africa, before he retired in 2017. Prior to Alere, he held senior commercial roles at Trinity Biotech. 

Apr 09, 2018

Paul Billings

Natera has appointed Paul Billings as its chief medical officer and senior vice president of medical affairs, where he will help lead efforts across the firm's reproductive health, oncology, and new emerging businesses. Billings is a board-certified internist and clinical geneticist with more than 30 years of experience in genomics and molecular medicine, having held academic and research appointments at Harvard University, UC San Francisco, Stanford University, and UC Berkeley.

Prior to joining Natera, Billings was chief medical officer of Life Technologies, consulting CMO of the genetic sciences division of Thermo Fisher Scientific, and senior physician at Laboratory Corporation of America. He has served on the scientific advisory board of the US Food and Drug Administration, the genomic medicine advisory committee at the Department of Veterans Affairs, and the HHS Secretary’s Advisory Committee on Genomics, Health and Society. His work formed the basis of the Genetic Information Nondiscrimination Act of 2008 (GINA).

Apr 09, 2018

John Anson, Paul Kenny

Oxford Gene Technology has announced that it has appointed John Anson as CEO, who previously served as executive VP of research and development. He will be replacing Mike Evans, who has become a non-executive director of OGT's board 

In addition, OGT has appointed Paul Kenny as executive VP of regulatory and medical affairs. Kenny previously served as head of regulatory affairs at The Binding Site. 

Apr 03, 2018

Ronnie Andrews, Cavan Redmond

OncoCyte has appointed Ronald Andrews to its board of directors, bringing its total number of directors to seven and its independent directors to four. Andrews has over 30 years' experience in the molecular diagnostics and genomics industries, and was founder and principal of the Bethesda Group, a company focused on helping organizations in the molecular diagnostics and genomics industries. Prior to founding Bethesda, he served as president of the Genetic Sciences Division at Thermo Fisher Scientific and president of the Medical Sciences Venture at Life Technologies. He was also CEO and segment leader of GE Molecular Diagnostics at Clarient from 2004 until 2012. Andrews currently serves on the board of directors of Insight Genetics, Orion Healthcare, and Oxford Immunotec.

OncoCyte also announced that Cavan Redmond has been appointed as chairman of its board of directors. He will be replacing Alfred Kinglsey, who will remain a director of the firm. Before his time at OncoCyte, Redmond previously served as CEO of WebMD. In addition, he has served as senior VP and group president at Pfizer. 

Apr 02, 2018

Melody Harris

Melody Harris has joined SomaLogic as chief legal officer. Most recently, she was vice president and chief counsel at Qualcomm Life, a digital health subsidiary of Qualcomm. Prior to that, Harris was general counsel at HealthyCircles. 

Mar 21, 2018

Grannum Sant

Exosome Diagnostics has appointed Grannum Sant as its head of medical affairs. Sant holds an appointment as Professor of Urology at Tufts University, where he has spent more than two decades. He has also served various leadership positions in research and professional societies, including a term as President of the New England Section of the American Urological Association.

Outside of academia, Sant worked as a pharma medical affairs and clinical development executive, serving as a vice president of medical affairs at both Sanofi-Aventis US, and at Genzyme. Most recently he was the medical affairs lead for OPKO Health.

Mar 20, 2018

Elaine Mardis

Elaine Mardis has been named president-elect of the American Association for Cancer Research for 2018-19. Her appointment will start next month in conjunction with the AACR annual meeting in Chicago, and she will become AACR president in April of 2019. Mardis holds the Nationwide Foundation Endowed Chair of Genomic Medicine and is the co-executive director of the Institute for Genomic Medicine at Nationwide Children's Hospital, and a professor of pediatrics at the Ohio State University College of Medicine. She holds a bachelor's degree and a PhD from the University of Oklahoma.  

Mar 20, 2018

Mark Stenhouse

Exact Sciences has appointed Mark Stenhouse to the new role of president for its flagship product Cologuard, a non-invasive stool-based DNA test for early detection of colorectal cancer. Stenhouse, who is currently serving as vice president of the US immunology group at AbbVie, will assume this new position on April 2. At AbbVie, Stenhouse leads the sales and marketing teams for the anti-inflammatory drug Humira. He has spent nearly 30 years at Abbott Laboratories/AbbVie, where he was first hired for a field sales position. He became national sales director in the US immunology-gastroenterology franchise, and rose to marketing director, followed by senior director of commercial initiatives. In 2010, Stenhouse was appointed a general manager within the company before being promoted to vice president.

Mar 20, 2018

George Cardoza, Sharon Virag

NeoGenomics announced the appointments of George Cardoza as president of the Pharma Services Division, and Sharon Virag as chief financial officer. The position of president of the Pharma Services Division is a newly created position. Cardoza, who has served as chief financial officer since 2009, will lead a division that grew revenues 69 percent to $8.7 million last year. The division also includes a new lab in Rolle, Switzerland that was added last year to meet Pharma Services demand. Virag, who is succeeding Cardoza in the chief financial officer role, was previously vice president, corporate finance and chief accounting officer, at Aetna. Her appointment is effective March 27.

Mar 12, 2018

Phil Febbo

Illumina has appointed Phil Febbo as chief medical officer. Starting March 26, 2018, Febbo will be responsible for developing and executing on Illumina's strategy to drive genomic testing into healthcare practice.

Prior to Joining Illumina, Febbo has served as CMO at Genomic Health, and before that he served as professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. While at UCSF, Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. He holds a BA degree in biology from Dartmouth College, received his MD at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. 

Mar 07, 2018

Lee-Jen Wei

Lee-Jen Wei was appointed to the scientific advisory board of VolitionRx. Wei is a professor of biostatistics at Harvard University where his research focused mainly on developing statistical methods for designing and analyzing clinical trials. He has developed numerous novel and widely used statistical methods.

Mar 07, 2018

Paul Limburg

Exact Sciences has appointed Paul Limburg as co-chief medical officer. Limburg is a gastroenterologist and a professor of medicine at the Mayo Clinic, and serves as a co-leader of the Cancer Prevention and Control program within the Mayo Clinic Cancer Center. While at Mayo, he has also served as medical director of its global business solutions unit, and as medical director of several of its health and well-being programs. Limburg will advise Exact Sciences on research opportunities to inform, expand, and accelerate the adoption of effective colon cancer screening options such as Cologuard. He will continue to serve as a gastroenterologist with Mayo Clinic's Division of Gastroenterology and Hepatology, co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center, and principal investigator for the NCI-funded cancer prevention network clinical trials consortium.

Pages